{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "acetylcholinesterase", "benzylpyridinium salts", "butyrylcholine esterase", "cholinesterase", "donepezil"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36226120", "DateRevised": {"Year": "2022", "Month": "10", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "26"}], "Language": ["eng"], "ELocationID": ["936240", "10.3389/fchem.2022.936240"], "Journal": {"ISSN": "2296-2646", "JournalIssue": {"Volume": "10", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in chemistry", "ISOAbbreviation": "Front Chem"}, "ArticleTitle": "Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer's disease.", "Pagination": {"StartPage": "936240", "MedlinePgn": "936240"}, "Abstract": {"AbstractText": ["<b>Background:</b> Alzheimer's disease (AD) is an advanced and irreversible degenerative disease of the brain, recognized as the key reason for dementia among elderly people. The disease is related to the reduced level of acetylcholine (ACh) in the brain that interferes with memory, learning, emotional, and behavior responses. Deficits in cholinergic neurotransmission are responsible for the creation and progression of numerous neurochemical and neurological illnesses such as AD. <b>Aim:</b> Herein, focusing on the fact that benzylpyridinium salts mimic the structure of donepezil hydrochlorideas a FDA-approved drug in the treatment of AD, their synthetic approaches and inhibitory activity against cholinesterases (ChEs) were discussed. Also, molecular docking results and structure-activity relationship (SAR) as the most significant concept in drug design and development were considered to introduce potential lead compounds. <i>Key scientific concepts:</i> AChE plays a chief role in the end of nerve impulse transmission at the cholinergic synapses. In this respect, the inhibition of AChE has been recognized as a key factor in the treatment of AD, Parkinson's disease, senile dementia, myasthenia gravis, and ataxia. A few drugs such as donepezil hydrochloride are prescribed for the improvement of cognitive dysfunction and memory loss caused by AD. Donepezil hydrochloride is a piperidine-containing compound, identified as a well-known member of the second generation of AChE inhibitors. It was established to treat AD when it was assumed that the disease is associated with a central cholinergic loss in the early 1980s. In this review, synthesis and anti-ChE activity of a library of benzylpyridinium salts were reported and discussed based on SAR studies looking for the most potent substituents and moieties, which are responsible for inducing the desired activity even more potent than donepezil. It was found that linking heterocyclic moieties to the benzylpyridinium salts leads to the potent ChE inhibitors. In this respect, this review focused on the recent reports on benzylpyridinium salts and addressed the structural features and SARs to get an in-depth understanding of the potential of this biologically improved scaffold in the drug discovery of AD."], "CopyrightInformation": "Copyright \u00a9 2022 Sepehri, Saeedi, Larijani and Mahdavi."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran."}, {"Identifier": [], "Affiliation": "Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran."}], "LastName": "Sepehri", "ForeName": "Saghi", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Saeedi", "ForeName": "Mina", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Larijani", "ForeName": "Bagher", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Mahdavi", "ForeName": "Mohammad", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Chem", "NlmUniqueID": "101627988", "ISSNLinking": "2296-2646"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abdullaha M., Nuthakki V. K., Bharate S. B. (2020). Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase. Eur. J. Med. Chem. 207, 112761. 10.1016/j.ejmech.2020.112761", "ArticleIdList": ["10.1016/j.ejmech.2020.112761", "32942070"]}, {"Citation": "Abedinifar F., Farnia S. M. F., Mahdavi M., Nadri H., Moradi A., Ghasemi J. B., et al. (2018). Synthesis and cholinesterase inhibitory activity of new 2-benzofuran carboxamide-benzylpyridinum salts. Bioorg. Chem. 80, 180\u2013188. 10.1016/j.bioorg.2018.06.006", "ArticleIdList": ["10.1016/j.bioorg.2018.06.006", "29929079"]}, {"Citation": "Agatonovic-Kustrin S., Kettle C., Morton D. W. (2018). A molecular approach in drug development for Alzheimer\u2019s disease. Biomed. Pharmacother. 106, 553\u2013565. 10.1016/j.biopha.2018.06.147", "ArticleIdList": ["10.1016/j.biopha.2018.06.147", "29990843"]}, {"Citation": "Akrami H., Mirjalili B. F., Khoobi M., Nadri H., Moradi A., Sakhteman A., et al. (2014). Indolinone-based acetylcholinesterase inhibitors: Synthesis, biologicalactivity and molecular modeling. Eur. J. Med. Chem. 84, 375\u2013381. 10.1016/j.ejmech.2014.01.017", "ArticleIdList": ["10.1016/j.ejmech.2014.01.017", "25036795"]}, {"Citation": "Alipour M., Khoobi M., Foroumadi A., Nadri H., Moradi A., Sakhteman A., et al. (2012). Novel coumarin derivatives bearing N-benzyl pyridinium moiety: potent and dual binding site acetylcholinesterase inhibitors. Bioorg. Med. Chem. 20, 7214\u20137222. 10.1016/j.bmc.2012.08.052", "ArticleIdList": ["10.1016/j.bmc.2012.08.052", "23140986"]}, {"Citation": "Alipour M., Khoobi M., Nadri H., Sakhteman A., Moradi A., Ghandi M., et al. (2013). Synthesis of some new 3-coumaranone and coumarin derivatives as dual inhibitors of acetyl- and butyrylcholinesterase. Arch. Pharm. Weinh. 346, 577\u2013587. 10.1002/ardp.201300080", "ArticleIdList": ["10.1002/ardp.201300080", "23852709"]}, {"Citation": "Arab S., Sadat-Ebrahimi S. E., Mohammadi-Khanaposhtani M., Moradi A., Nadri H., Mahdavi M., et al. (2015). Synthesis and evaluation of chroman-4-one linked to N-benzyl pyridinium derivatives as new acetylcholinesterase inhibitors. Arch. Pharm. Weinh. 348, 643\u2013649. 10.1002/ardp.201500149", "ArticleIdList": ["10.1002/ardp.201500149", "26192069"]}, {"Citation": "Baharloo F., Moslemin M. H., Nadri H., Asadipour A., Mahdavi M., Emami S., et al. (2015). Benzofuran-derived benzylpyridinium bromides as potentacetylcholinesterase inhibitors. Eur. J. Med. Chem. 93, 196\u2013201. 10.1016/j.ejmech.2015.02.009", "ArticleIdList": ["10.1016/j.ejmech.2015.02.009", "25681712"]}, {"Citation": "Bartus R. T. (2000). On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163, 495\u2013529. 10.1006/exnr.2000.7397", "ArticleIdList": ["10.1006/exnr.2000.7397", "10833325"]}, {"Citation": "Baussanne I., Firstova O., Dediu A. B., Larosa C., Furdui B., Ghinea I. O., et al. (2021). Interest of novel N-alkylpyridinium-indolizine hybrids in the field of Alzheimer\u2019s disease: Synthesis, characterization and evaluation of antioxidant activity, cholinesterase inhibition, and amyloid fibrillation interference. Bioorg. Chem. 116, 105390. 10.1016/j.bioorg.2021.105390", "ArticleIdList": ["10.1016/j.bioorg.2021.105390", "34670332"]}, {"Citation": "Bekris L. M., Yu C. E., Bird T. D., Tsuang D. W. (2010). Review article: genetics of alzheimer disease. J. Geriatr. Psychiatry Neurol. 23, 213\u2013227. 10.1177/0891988710383571", "ArticleIdList": ["10.1177/0891988710383571", "PMC3044597", "21045163"]}, {"Citation": "Brus B., Kosak U., Turk S., Pislar A., Coquelle N., Kos J., et al. (2014). Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J. Med. Chem. 57, 8167\u20138179. 10.1021/jm501195e", "ArticleIdList": ["10.1021/jm501195e", "25226236"]}, {"Citation": "Cacabelos R. (2007). Donepezil in Alzheimer\u2019s disease: From conventional trials to pharmacogenetics. Neuropsychiatr. Dis. Treat. 3, 303\u2013333.", "ArticleIdList": ["PMC2654795", "19300564"]}, {"Citation": "Calsolaro V., Edison P. (2016). Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimer's. Dement. 12, 719\u2013732. 10.1016/j.jalz.2016.02.010", "ArticleIdList": ["10.1016/j.jalz.2016.02.010", "27179961"]}, {"Citation": "Costanzo P., Cariati L., Desiderio D., Sgammato R., Lamberti A., Arcone R., et al. (2016). Design, synthesis, and evaluation of donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Med. Chem. Lett. 7, 470\u2013475. 10.1021/acsmedchemlett.5b00483", "ArticleIdList": ["10.1021/acsmedchemlett.5b00483", "PMC4867475", "27190595"]}, {"Citation": "Dubey S. K., Kharbanda M., Dubey S. K., Mathela C. S. (2010). A new commercially viable synthetic route for donepezil hydrochloride: anti-Alzheimer\u2019s drug. Chem. Pharm. Bull. 58 (9), 1157\u20131160. 10.1248/cpb.58.1157", "ArticleIdList": ["10.1248/cpb.58.1157", "20823593"]}, {"Citation": "Garcia-Ayllon M. S., Small D. H., Avila J., Saez-Valero J. (2011). Revisiting the role of acetylcholinesterase in Alzheimer\u2019s disease: Cross-talk with P-tau and \u03b2-amyloid. Front. Mol. Neurosci. 4, 22. 10.3389/fnmol.2011.00022", "ArticleIdList": ["10.3389/fnmol.2011.00022", "PMC3171929", "21949503"]}, {"Citation": "Ghotbi G., Mahdavi M., Najaf Z., Moghadam F. H., Hamzeh-Mivehroud M., Davaran S., et al. (2020). Design, synthesis, biological evaluation, and docking study of novel dualacting thiazole-pyridiniums inhibiting acetylcholinesterase and \u03b2-amyloid aggregation for Alzheimer\u2019s disease. Bioorg. Chem. 103, 104186. 10.1016/j.bioorg.2020.104186", "ArticleIdList": ["10.1016/j.bioorg.2020.104186", "32890993"]}, {"Citation": "Girek M., Szymanski P. (2019). Tacrine hybrids as multi-target-directed ligands in Alzheimer\u2019s disease: Influence of chemical structures on biological activities. Chem. Pap. 73, 269\u2013289. 10.1007/s11696-018-0590-8", "ArticleIdList": ["10.1007/s11696-018-0590-8"]}, {"Citation": "Goyal D. D., Shuaib S., Mann S., Goyal B. (2017). Rationally designed peptides and peptidomimetics as inhibitors of amyloid-\u03b2 (A\u03b2) aggregation: potential therapeutics of Alzheimer\u2019s disease. ACS Comb. Sci. 19, 55\u201380. 10.1021/acscombsci.6b00116", "ArticleIdList": ["10.1021/acscombsci.6b00116", "28045249"]}, {"Citation": "Hassanzadeh M., Hassanzadeh F., khodarahmi G. A., Rostami M., Azimi F., Nadri H., et al. (2021). Design, synthesis, and bio-evaluation of new isoindoline-1, 3-dione derivatives as possible inhibitors of acetylcholinesterase. Res. Pharm. Sci. 16, 482\u2013492. 10.4103/1735-5362.323915", "ArticleIdList": ["10.4103/1735-5362.323915", "PMC8407153", "34522196"]}, {"Citation": "Hosseini F., Ramazani A., Mohammadi-Khanaposhtani M., Tehrani M. B., Nadri H., Larijani B., et al. (2019). Design, synthesis, and biological evaluation of novel 4-oxobenzo[d]1, 2, 3-triazin-benzylpyridinum derivatives as potent anti-Alzheimer agents. Bioorg. Med. Chem. 27, 2914\u20132922. 10.1016/j.bmc.2019.05.023", "ArticleIdList": ["10.1016/j.bmc.2019.05.023", "31128990"]}, {"Citation": "Jiang X. Y., Chen T. K., Zhou J. T., He S. Y., Yang H. Y., Chen Y., et al. (2018). Dual GSK-3\u03b2/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer\u2019s disease drug discovery. ACS Med. Chem. Lett. 9, 171\u2013176. 10.1021/acsmedchemlett.7b00463", "ArticleIdList": ["10.1021/acsmedchemlett.7b00463", "PMC5846044", "29541355"]}, {"Citation": "Khoobi M., Alipour M., Sakhteman A., Nadri H., Moradi A., Ghandi M., et al. (2013). Design, synthesis, biological evaluation and docking study of 5-oxo-4, 5-dihydropyrano[3, 2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Eur. J. Med. Chem. 68, 260\u2013269. 10.1016/j.ejmech.2013.07.038", "ArticleIdList": ["10.1016/j.ejmech.2013.07.038", "23988409"]}, {"Citation": "Khorana N., Changwichit K., Ingkaninan K., Utsintong M. (2012). Prospective acetylcholinesterase inhibitory activity of indole and its analogs. Bioorg. Med. Chem. Lett. 22, 2885\u20132888. 10.1016/j.bmcl.2012.02.057", "ArticleIdList": ["10.1016/j.bmcl.2012.02.057", "22425563"]}, {"Citation": "Khunnawutmanotham N., Chimnoi N., Saparpakorn P., Techasakul S. (2016). Synthesis and anti-acetylcholinesterase activity of scopoletin derivatives. Bioorg. Chem. 65, 137\u2013145. 10.1016/j.bioorg.2015.12.002", "ArticleIdList": ["10.1016/j.bioorg.2015.12.002", "26943478"]}, {"Citation": "Khunnawutmanotham N., Laongthipparos C., Saparpakorn P., Chimnoi N., Techasakul S. (2018). Synthesis of 3-aminocoumarin-N-benzylpyridinium conjugates with nanomolar inhibitory activity against acetylcholinesterase. Beilstein J. Org. Chem. 14, 2545\u20132552. 10.3762/bjoc.14.231", "ArticleIdList": ["10.3762/bjoc.14.231", "PMC6204823", "30410615"]}, {"Citation": "Knowles J. (2006). Donepezil in Alzheimer\u2019s disease: An evidence-based review of its impact on clinical and economic outcomes. Core Evid. 1, 195\u2013219.", "ArticleIdList": ["PMC3321665", "22500154"]}, {"Citation": "Komloova M., Horova A., Hrabinova M., Jun D., Dolezal M., Vinsova J., et al. (2013). Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors. Bioorg. Med. Chem. Lett. 23, 6663\u20136666. 10.1016/j.bmcl.2013.10.043", "ArticleIdList": ["10.1016/j.bmcl.2013.10.043", "24220173"]}, {"Citation": "Kryger G., Silman I., Sussman J. L. (1999). Structure of acetylcholinesterase complexed with E2020 (Aricept): Implications for the design of new anti-alzheimer drugs. Structure 15, 297\u2013307. 10.1016/s0969-2126(99)80040-9", "ArticleIdList": ["10.1016/s0969-2126(99)80040-9", "10368299"]}, {"Citation": "Lan J. S., Hou J. W., Liu Y., Ding Y., Zhang Y., Lia L., et al. (2017). Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer\u2019s disease. J. Enzyme Inhib. Med. Chem. 32, 776\u2013788. 10.1080/14756366.2016.1256883", "ArticleIdList": ["10.1080/14756366.2016.1256883", "PMC6009898", "28585866"]}, {"Citation": "Lan J. S., Zhang T., Liu Y., Yang J., Xie S. S., Liu J., et al. (2017). Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. Eur. J. Med. Chem. 133, 184\u2013196. 10.1016/j.ejmech.2017.02.045", "ArticleIdList": ["10.1016/j.ejmech.2017.02.045", "28388521"]}, {"Citation": "Lan J. S., Ding Y., Liu Y., Kang P., Hou J. W., Zhang X. Y., et al. (2017). Design, synthesis and biological evaluation of novel coumarin-Nbenzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 139, 48\u201359. 10.1016/j.ejmech.2017.07.055", "ArticleIdList": ["10.1016/j.ejmech.2017.07.055", "28797883"]}, {"Citation": "Lavado L., Zhang M. H., Patel K., Khan S., Patel U. K. (2019). Biometals as potential predictors of the neurodegenerative decline in Alzheimer\u2019s disease. Cureus 11, e5573. 10.7759/cureus.5573", "ArticleIdList": ["10.7759/cureus.5573", "PMC6820671", "31695992"]}, {"Citation": "Lee J. K., Kim N. J. (2017). Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer\u2019s disease. Molecules 22, 1287. 10.3390/molecules22081287", "ArticleIdList": ["10.3390/molecules22081287", "PMC6152076", "28767069"]}, {"Citation": "Li Q., Yang H., Chen Y., Sun H. (2017). Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Eur. J. Med. Chem. 132, 294\u2013309. 10.1016/j.ejmech.2017.03.062", "ArticleIdList": ["10.1016/j.ejmech.2017.03.062", "28371641"]}, {"Citation": "Li Q., He S., Chen Y., Feng F., Qu W., Sun H. (2018). Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease. Eur. J. Med. Chem. 158, 463\u2013477. 10.1016/j.ejmech.2018.09.031", "ArticleIdList": ["10.1016/j.ejmech.2018.09.031", "30243151"]}, {"Citation": "Luo X. T., Wang C. M., Liu Y., Huang Z. G. (2015). New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease. Eur. J. Med. Chem. 103, 302\u2013311. 10.1016/j.ejmech.2015.08.052", "ArticleIdList": ["10.1016/j.ejmech.2015.08.052", "26363866"]}, {"Citation": "Mack A., Robitzki A. (2000). The key role of butyrylcholinesterase during neurogenesis and neural disorders: An antisense-5'butyrylcholinesterase-DNA study. Prog. Neurobiol. 60, 607\u2013628. 10.1016/s0301-0082(99)00047-7", "ArticleIdList": ["10.1016/s0301-0082(99)00047-7", "10739090"]}, {"Citation": "Makarian M., Gonzalez M., Salvador S. M., Lorzadeh S., Hudson P. K., Pecic S. (2022). Synthesis, kinetic evaluation and molecular docking studies of donepezil-based acetylcholinesterase inhibitors. J. Mol. Struct. 1247, 131425. 10.1016/j.molstruc.2021.131425", "ArticleIdList": ["10.1016/j.molstruc.2021.131425", "PMC8881002", "35221376"]}, {"Citation": "Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. (2010). Alzheimer\u2019s disease: Clinical trials and drug development. Lancet Neurol. 9, 702\u2013716. 10.1016/s1474-4422(10)70119-8", "ArticleIdList": ["10.1016/s1474-4422(10)70119-8", "20610346"]}, {"Citation": "Matsuzaki K. (2011). formation of toxic amyloid fibrils by amyloid \u03b2-protein on ganglioside clusters. Int. J. Alzheimer's. Dis. 2011, 1\u20137. 10.4061/2011/956104", "ArticleIdList": ["10.4061/2011/956104", "PMC3034960", "21318142"]}, {"Citation": "McGleenon B. M., Dynan K. B., Passmore A. P. (1999). Acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Br. J. Clin. Pharmacol. 48, 471\u2013480. 10.1046/j.1365-2125.1999.00026.x", "ArticleIdList": ["10.1046/j.1365-2125.1999.00026.x", "PMC2014378", "10583015"]}, {"Citation": "Mesulam M. M., Guillozet A., Shaw P., Levey A., Duysen E. G., Lockridge O. (2002). Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110, 627\u2013639. 10.1016/s0306-4522(01)00613-3", "ArticleIdList": ["10.1016/s0306-4522(01)00613-3", "11934471"]}, {"Citation": "Miao J., Shi R., Li L., Chen F., Zhou Y., Tung Y. C., et al. (2019). Pathological tau from Alzheimer\u2019s brain induces site-specific hyperphosphorylation and SDS- and reducing agent-resistant aggregation of tau in vivo . Front. Aging Neurosci. 11, 34. 10.3389/fnagi.2019.00034", "ArticleIdList": ["10.3389/fnagi.2019.00034", "PMC6411797", "30890929"]}, {"Citation": "Mohsin N. A., Ahmad M. (2020). Donepezil: A review of the recent structural modifications and their impact on anti-alzheimer activity. Braz. J. Pharm. Sci. 56, e18325. 10.1590/s2175-97902019000418325", "ArticleIdList": ["10.1590/s2175-97902019000418325"]}, {"Citation": "Mollazadeh M., Mohammadi-Khanaposhtani M., Zonouzi A., Nadri H., Najafi Z., Larijani B., et al. (2019). New benzyl pyridinium derivatives bearing 2, 4-dioxochroman moiety as potent agents for treatment of Alzheimer\u2019s disease: Design, synthesis, biological evaluation, and docking study. Bioorg. Chem. 87, 506\u2013515. 10.1016/j.bioorg.2019.03.012", "ArticleIdList": ["10.1016/j.bioorg.2019.03.012", "30928873"]}, {"Citation": "Mostofi M., Mohammadi Ziarani G., Mahdavi M., Moradi A., Nadri H., Emami S., et al. (2015). Synthesis and structure-activity relationship study of benzofuranbased chalconoids bearing benzylpyridinium moiety as potent acetylcholinesterase inhibitors. Eur. J. Med. Chem. 103, 361\u2013369. 10.1016/j.ejmech.2015.08.061", "ArticleIdList": ["10.1016/j.ejmech.2015.08.061", "26363872"]}, {"Citation": "Mushtaq G., Greig N. H., Khan J. A., Kamal M. A. (2014). Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer\u2019s disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets. 13, 1432\u20131439. 10.2174/1871527313666141023141545", "ArticleIdList": ["10.2174/1871527313666141023141545", "PMC5878042", "25345511"]}, {"Citation": "Musilek K., Komloova M., Zavadova V., Holas O., Hrabinova M., Pohanka M., et al. (2010). Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. Bioorg. Med. Chem. Lett. 20, 1763\u20131766. 10.1016/j.bmcl.2010.01.034", "ArticleIdList": ["10.1016/j.bmcl.2010.01.034", "20138518"]}, {"Citation": "Musilek K., Komloova M., Holas O., Hrabinova M., Pohanka M., Dohnal V., et al. (2011). Preparation and in vitro screening of symmetrical bis-isoquinoliniumcholinesterase inhibitors bearing various connecting linkage-implicationsfor early myasthenia gravis treatment. Eur. J. Med. Chem. 46, 811\u2013818. 10.1016/j.ejmech.2010.12.011", "ArticleIdList": ["10.1016/j.ejmech.2010.12.011", "21236521"]}, {"Citation": "Nadri H., Pirali-Hamedani M., Shekarchi M., Abdollahi M., Sheibani V., Amanlou M., et al. (2010). Design, synthesis and anticholinesterase activity of a novel seriesof 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives. Bioorg. Med. Chem. 18, 6360\u20136366. 10.1016/j.bmc.2010.07.012", "ArticleIdList": ["10.1016/j.bmc.2010.07.012", "20673725"]}, {"Citation": "Nadri H., Pirali-Hamedani M., Moradi A., Sakhteman A., Vahidi A., Sheibani V., et al. (2013). 5, 6-Dimethoxybenzofuran-3-one derivatives: A novel series of dual acetylcholinesterase/butyrylcholinesterase inhibitors bearing benzylpyridinium moiety. DARU J. Pharm. Sci. 21, 15. 10.1186/2008-2231-21-15", "ArticleIdList": ["10.1186/2008-2231-21-15", "PMC3599263", "23445881"]}, {"Citation": "Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J. C., Nachon F. (2003). Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 278, 41141\u201341147. 10.1074/jbc.m210241200", "ArticleIdList": ["10.1074/jbc.m210241200", "12869558"]}, {"Citation": "Nordberg A., Ballard C., Bullock R., Darreh-Shori T., Somogyi M. (2013). A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer\u2019s disease. Prim. Care Companion CNS Disord. 15, PCC.12r01412. 10.4088/pcc.12r01412", "ArticleIdList": ["10.4088/pcc.12r01412", "PMC3733526", "23930233"]}, {"Citation": "Palin R., Clark J. K., Cowley P., Muir A. W., Pow E., Prosser A. B., et al. (2002). Novel piperidinium and pyridinium agents as water-soluble acetylcholinesterase inhibitors for the reversal of neuromuscular blockade. Bioorg. Med. Chem. Lett. 12, 2569\u20132572. 10.1016/s0960-894x(02)00483-3", "ArticleIdList": ["10.1016/s0960-894x(02)00483-3", "12182862"]}, {"Citation": "Parlar S., Bayraktar G., Tarikogullari A. H., Alpt\u00fcz\u00fcn V., Erciyas E. (2016). Synthesis, biological evaluation and molecular docking study of hydrazone-containing pyridinium salts as cholinesterase inhibitors. Chem. Pharm. Bull. 64, 1281\u20131287. 10.1248/cpb.c16-00221", "ArticleIdList": ["10.1248/cpb.c16-00221", "27581632"]}, {"Citation": "Peng D. Y., Sun Q., Zhu X. L., Lin H. Y., Chen Q., Yu N. X., et al. (2012). Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, A\u03b2 aggregation, and \u03b2-secretase. Bioorg. Med. Chem. 20, 6739\u20136750. 10.1016/j.bmc.2012.09.016", "ArticleIdList": ["10.1016/j.bmc.2012.09.016", "23041347"]}, {"Citation": "Picciotto M. R., Higley M. J., Mineur Y. S. (2012). Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116\u2013129. 10.1016/j.neuron.2012.08.036", "ArticleIdList": ["10.1016/j.neuron.2012.08.036", "PMC3466476", "23040810"]}, {"Citation": "Piemonyese L., Tomas D., Hiremathad A., Capriati V., Candeias E., Cardoso S. M., et al. (2018). Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer\u2019s drug candidates. J. Enzyme Inhib. Med. Chem. 33, 1212\u20131224. 10.1080/14756366.2018.1491564", "ArticleIdList": ["10.1080/14756366.2018.1491564", "PMC6127844", "30160188"]}, {"Citation": "Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C. P. (2013). The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's. &amp. Dement. 9, 63\u201375. 10.1016/j.jalz.2012.11.007", "ArticleIdList": ["10.1016/j.jalz.2012.11.007", "23305823"]}, {"Citation": "Rawat A. S., Pande S., Bhatt N., Kharatkar R., Belwal C., Vardhan A. (2013). Synthesis of donepezil hydrochloride via chemoselective hydrogenation. Org. Process Res. Dev. 17, 1617. 10.1021/op400007p", "ArticleIdList": ["10.1021/op400007p"]}, {"Citation": "Rook Y., Schmidtke K. U., Gaube F., Schepmann D., Wunsch B., Heilmann J., et al. (2010). Bivalent \u03b2-carbolines as potential multitarget anti-alzheimer agents. J. Med. Chem. 53, 3611\u20133617. 10.1021/jm1000024", "ArticleIdList": ["10.1021/jm1000024", "20361801"]}, {"Citation": "Saeedi M., Golipoor M., Mahdavi M., Moradi A., Nadri H., Emami S., et al. (2016). Phthalimide-derived N-benzylpyridinium halides targeting cholinesterases: synthesis and bioactivity of new potential anti-alzheimer\u2019s disease agents. Arch. Pharm. Weinh. 349, 293\u2013301. 10.1002/ardp.201500425", "ArticleIdList": ["10.1002/ardp.201500425", "26898241"]}, {"Citation": "Salehi N., Mirjalili B. F., Nadri H., Abdolahi Z., Forootanfar H., Samzadeh-Kermani A., et al. (2019). Synthesis and biological evaluation of new N-benzylpyridinium-basedbenzoheterocycles as potential anti-Alzheimer\u2019s agents. Bioorg. Chem. 83, 559\u2013568. 10.1016/j.bioorg.2018.11.010", "ArticleIdList": ["10.1016/j.bioorg.2018.11.010", "30471578"]}, {"Citation": "Shafferman A., Kronman C., Flashner Y., Leitner M., Grosfeld H., Ordentlich A., et al. (1992). Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J. Biol. Chem. 267, 17640\u201317648. 10.1016/s0021-9258(19)37091-7", "ArticleIdList": ["10.1016/s0021-9258(19)37091-7", "1517212"]}, {"Citation": "Sharma K. (2019). Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Mol. Med. Rep. 20, 1479\u20131487.", "ArticleIdList": ["PMC6625431", "31257471"]}, {"Citation": "Shen H., Kihara T., Hongo H., Wu X., Kem W. R., Shimohama S., et al. (2010). Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of \u03b17 nicotinic receptors and internalization of NMDA receptors. Br. J. Pharmacol. 161, 127\u2013139. 10.1111/j.1476-5381.2010.00894.x", "ArticleIdList": ["10.1111/j.1476-5381.2010.00894.x", "PMC2962822", "20718745"]}, {"Citation": "Shi D. H., Huang W., Li C., Wang L. T., Wang S. F. (2013). Synthesis, biological evaluation and molecular modeling of aloe-emodin derivatives as new acetylcholinesterase inhibitors. Bioorg. Med. Chem. 21, 1064\u20131073. 10.1016/j.bmc.2013.01.015", "ArticleIdList": ["10.1016/j.bmc.2013.01.015", "23380475"]}, {"Citation": "Shuai W., Li W., Yin Y., Yang L., Xu F., Xu S., et al. (2019). Design, synthesis and molecular modeling of isothiochromanone derivatives as acetylcholinesterase inhibitors. Future Med. Chem. 11, 2687\u20132699. 10.4155/fmc-2019-0125", "ArticleIdList": ["10.4155/fmc-2019-0125", "31596141"]}, {"Citation": "Stanciu G. D., Luca A., Rusu R. N., Bild V., Chiriac S. I. B., Solcan C., et al. (2020). Alzheimer\u2019s disease pharmacotherapy in relation to cholinergic system involvement. Biomolecules 10, 40. 10.3390/biom10010040", "ArticleIdList": ["10.3390/biom10010040", "PMC7022522", "31888102"]}, {"Citation": "Sugimoto H., Ogura H., Arai Y., Iimura Y., Yamanishi Y. (2002). Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 89, 7\u201320. 10.1254/jjp.89.7", "ArticleIdList": ["10.1254/jjp.89.7", "12083745"]}, {"Citation": "Taylor P., Radic Z. (1994). The cholinesterases: from genes to proteins. Annu. Rev. Pharmacol. Toxicol. 34, 281\u2013320. 10.1146/annurev.pa.34.040194.001433", "ArticleIdList": ["10.1146/annurev.pa.34.040194.001433", "8042853"]}, {"Citation": "Tonnies E., Trushina E. (2017). Oxidative stress, synaptic dysfunction, and Alzheimer\u2019s disease. J. Alzheimers Dis. 57, 1105\u20131121. 10.3233/jad-161088", "ArticleIdList": ["10.3233/jad-161088", "PMC5409043", "28059794"]}, {"Citation": "Vafadarnejad F., Mahdavi M., Karimpour-Razkenari E., Edraki N., Sameem B., Khanavi M., et al. (2018). Design and synthesis of novel coumarin-pyridinium hybrids: In vitro cholinesterase inhibitory activity. Bioorg. Chem. 77, 311\u2013319. 10.1016/j.bioorg.2018.01.013", "ArticleIdList": ["10.1016/j.bioorg.2018.01.013", "29421707"]}, {"Citation": "Wake R., Araki T., Miyaoka T., Nagahama M., Furuya M., Hayashida M., et al. (2018). Long-term effects of combined treatment with memantine and donepezil on Alzheimer\u2019s disease patients: 72-Week study. Neuropsychiatry (London) 8, 951\u2013960. 10.4172/neuropsychiatry.1000421", "ArticleIdList": ["10.4172/neuropsychiatry.1000421"]}, {"Citation": "Wang C., Wua Z., Cai H., Xu S., Liu J., Jiang J., et al. (2015). Design, synthesis, biological evaluation and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 25, 5212\u20135216. 10.1016/j.bmcl.2015.09.063", "ArticleIdList": ["10.1016/j.bmcl.2015.09.063", "26454504"]}, {"Citation": "Wu J., Ishikawa M., Zhang J., Hashimoto K. (2010). Brain imaging of nicotinic receptors in alzheimer's disease. Int. J. Alzheimer's. Dis. 2010, 1\u201311. 10.4061/2010/548913", "ArticleIdList": ["10.4061/2010/548913", "PMC3022172", "21253523"]}, {"Citation": "Yu L., Cao R., Yi W., Yan Q., Chen Z., Ma L., et al. (2010). Synthesis and binding ability of 1, 2, 3-triazole-based triterpenoid receptors for recognition of Hg(2+) ion. Bioorg. Med. Chem. Lett. 20, 3254\u20133258. 10.1016/j.bmcl.2010.04.059", "ArticleIdList": ["10.1016/j.bmcl.2010.04.059", "20452769"]}, {"Citation": "Yu Q., Holloway H. W., Luo W., Lahiri D. K., Brossi A., Greig N. H. (2010). Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg. Med. Chem. 18, 4687\u20134693. 10.1016/j.bmc.2010.05.022", "ArticleIdList": ["10.1016/j.bmc.2010.05.022", "PMC2989343", "20627738"]}, {"Citation": "Zarei S., Shafiei M., Firouzi M., Firoozpour L., Divsalar K., Asadipour A., et al. (2021). Design, synthesis and biological assessment of new 1 -benzyl-4-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium derivatives (BOPs) as potential dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Heliyon 7, e06683. 10.1016/j.heliyon.2021.e06683", "ArticleIdList": ["10.1016/j.heliyon.2021.e06683", "PMC8045006", "33869871"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "5", "Day": "5"}, {"Year": "2022", "Month": "7", "Day": "6"}, {"Year": "2022", "Month": "10", "Day": "13", "Hour": "2", "Minute": "47"}, {"Year": "2022", "Month": "10", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "14", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["36226120", "PMC9549744", "10.3389/fchem.2022.936240", "936240"]}}], "PubmedBookArticle": []}